The JAK1/3-Inhibitor R507 Diminishes Acute and Chronic Rejection While Demonstrating Immune Cell Specificity

patients with CLAD (5 BOS and 3 RAS with no evidence of infection, median 24 months after bilateral lung transplantation) and 8 matched stable patients were included in this study. RAS was defined as CLAD (irreversible decline in forced expiratory volume in 1 second (FEV1 80% baseline)) with irreversible decline in total lung capacity (TLC 90% baseline). BOS was defined as CLAD without RAS. Cytokine expression was measured in BALF by Luminex-based multiplex cytokine array. Results: Median FEV1 and TLC to baseline were 98% and 100% in stable patients, 68% and 102% in BOS and 40% and 63% in RAS. CXCL1, 8, 9, 12 and HGF were upregulated in CLAD compared with stable patients. Strikingly, IL-6/IL-10 ratio and the concentration of RANTES was significantly elevated in RAS compared to BOS (p 0.025 in both), while lymphotoxinwas upregulated in BOS (p 0.025).